Close

Join us for a day of learning and connecting Register Free Today

Immunotherapy for Bladder Cancer
Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link
  • About Immunotherapy
  • CRI's Impact
  • Related News & Resources

What Makes Immunotherapy a Promising Treatment for Bladder Cancer?

Reviewed By: Padmanee Sharma, M.D., Ph.D.
Details
The University of Texas MD Anderson Cancer Center, Houston, TX
Share

One of the most common cancers in the U.S., bladder cancer affects men more likely than women—with an estimated 77,000 new cases predicted to be diagnosed in 2016, and approximately 16,000 deaths expected. Because of the recurrent nature of bladder cancer, patients with bladder cancer must monitor their health closely for an extended period of time.

Immunotherapy has seen and continues to deliver promising results in the treatment of bladder cancer—the first diagnosis for which immunotherapy the Food and Drug Administration (FDA) granted approval in 1990. Since last year, two checkpoint inhibitors—atezolizumab and nivolumab—were also approved for bladder cancer, and there are numerous additional immune-based treatments for bladder cancer currently in development, with immunotherapy clinical trials for bladder cancer patients on the rise.

Bladder cancer immunotherapy has significantly reduced the risk of recurrence for bladder cancer, while also increasing the percentage of patients who see a complete response post-surgery. Investigational bladder cancer immunotherapies—those that "train" the body's immune system to recognize bladder cancer cells—have the potential to further improve the general outcomes for patients with this disease.

CRI's Impact on Bladder Cancer

Thanks to groundbreaking advancements in immunology research and clinical trials, immunotherapy has become one of the most promising bladder cancer treatments of our time.

Currently, the overall 5-year survival rate for bladder cancer is 77%—a rate which has not changed significantly over the last 10 years. Additionally, no new drugs for bladder cancer were approved by the FDA during this time.

New and developing bladder cancer immunotherapies have the potential to reduce recurrence rates and improve survival rates for patients with bladder cancer. Join us as we work to change the future of bladder cancer treatment—forever.

Featured Story

No one is cowering under a blanket.

Deborah Wassertzug
Melanoma  |  Diagnosed April 2013 - melanoma September 2014 - metastatic melanoma
Read My Story

 

Changing the Future of Cancer Research

As a science-first organization dedicated to supporting cancer immunotherapy research, we're funding a future that fights back against cancer—all with your help.

Support our mission to cure ALL cancers, for good.

Make a Donation

Join Team CRI by supporting our many dedicated fundraisers.

Support the Cause

*Immunotherapy results may vary from patient to patient.

Contact Us

National Headquarters | One Exchange Plaza
55 Broadway, Suite 1802 | New York, NY 10006

(800) 992-2623(212) 832-9376Staff Directory

Stay Connected with CRI

Follow us
Top